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urvey. 38% of cases of candidaemia were caused by C. albi-
ans and 62% by non-albicans strains.
Methods: 92 episodes in 92 patients with fungaemia and
vailable clinical data were analysed according to data from
RFs. Informations about risk factors, antifungal treatment
nd outcome 4 weeks after the onset of infection were col-
ected.
Results: All patients except 16.3% were adults >18 years
ld. Majority of patients were hospitalized on ICU (59.7%);
3.4% of patients had cancer and 16.3% had haematological
alignancy. 20% of patients were neutropenic at the onset
f candidaemia. Previous antibacterial treatment (93.4%),
nserted central venous catheter (83.6%), total parenteral
utrition (55.4%), surgical procedure (52%) and colonisation
ith Candida spp. were the most common risk factors asso-
iated with candidaemia. Fluconazole was the preferred
st line drug (58.6% of all treated patients) followed by
oriconazole (18.4%) and Amphotericin B (10.8%). 6 patients
6.5%) did not receive any antifungal therapy - 2/6 died and
/6 survived.
Fungaemia-related and candidaemia-related mortality
as 33.7% and 27.2%, respectively. 16/25 (64%) deaths were
ue to candidaemia caused by non-albicans candida strains
nd 9/25 (36%) were associated with C.albicans.
Conclusion: Mortality of patients with candidaemia
eﬂects the epidemiological trend in Slovakia where major-
ty of cases are caused by non-albicans strains. The choice of
ntifungal therapy should be in concordance with epidemi-
logical data.
oi:10.1016/j.ijid.2010.02.1763
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Background: To describe the percentage of Cryptococ-
us neoformans and Cryptococcus gattii encountered in our
ospital, a 2500-bed teaching hospital of São Paulo, and
o compare minimal inhibitory concentrations to different
ntifungal drugs.
Methods: Consecutive and no duplicate clinical isolates
ecovered from patients with infections (meningitis, cryp-
ococcaemia, pneumonia and peritonitis) between 2006 and
008 were included for analysis. Identiﬁcation to the species
evel was performed by conventional methods based on
rowth appearance on Sabouraud dextrose agar at 37 ◦C,
A
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roduction of urease and the presence of a capsule. Results
ere conﬁrmed using the API 20C (bioMerieux, St Louis,
SA). L-canavanine-glycine-bromothymol blue agar (CGB)
as used to distinguish C. gattii from C. neoformans. Min-
mal inhibitory concentrations (MIC) to amphotericin B,
aspofungin, 5-ﬂuorocytosine, posaconazole, ﬂuconazole,
traconazole and voriconazole were determined using Sen-
ititre Yeast-One Y8TM (TREK Diagnostic Systems, Cleveland,
SA).
Results: In the study period 43 isolates were included.
hirty three (77%) were C. neoformans and 10 (23%) were
. gatti. C. neoformans MIC 50/90 for antifungal drugs were
s follow: amphotericin B.(0.5mg/L -1mg/L,) caspofungin
16mg/L-16mg/L), posaconazol (0.064mg/L-0.25mg/L),
uconazole, (4mg/L-16mg/L); itraconazol (0.125mg/L-
.5mg/L) and voriconazol (0.032mg/L-0.125mg/L) C.
atti MIC 50/90mg/L for antifungal drugs were as
ollow: amphotericin: (0.5 -1mg/L); caspofungin (16mg/L-
2mg/L); posaconazole (0.125mg/L-0.25mg/l); ﬂucona-
ole: (8mg/L-16mg/L); itraconazole (0.25mg/L-0.5mg/L)
nd for voriconazole (0.125mg/L-0.25 mg/L). Fluconazole
ICs equal or higher than 16mg/L was observed among 40%
f C. gattii and only 18% among C. neoformans isolates.
Conclusion: Species identiﬁcation among Cryptococcus
pp isolates is an important epidemiological tool and should
e done in a routine basis. C gattii showed higher ﬂucona-
ole MICs and it should be closed monitored.
oi:10.1016/j.ijid.2010.02.1764
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Background: We describe two immunocompromised
atients with ultimately fatal esophageal pathology and Sac-
haromyces cerevisiae fungemia. Originally misidentiﬁed by
itek automated techniques, both yeast were ultimately
dentiﬁed by D1/D2 LSU rRNA gene sequence. Neither
atient had received probiotics.
Methods: Case 1: A 49-year-old intoxicated homeless
ale with a history of chronic alcoholism was admitted
or workup of hypoxia. Patient described a chronic cough
nd a 60 pound weight loss over six months. Examination
as notable for cachexia, poor dentition, and inspiratory
tidor. CT scan revealed a neck mass compromising the
atient’s airway. A PET scan demonstrated a hyperme-
abolic mass in the mediastinum with paratracheal lymph
ode uptake consistent with metastatic malignant disease.
ygosaccharomyces bailii was identiﬁed in blood cultures
rom admission and on hospital day three. Intravenous
mphotericin B treatment was initiated. Subsequent cul-
ures were negative.
Results: Case 2: An 87-year-old woman with hiatal hernia
as admitted with gastrointestinal obstruction. Examination
